| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC2116 |
| Trial ID | NCT03954106 |
| Disease | Neurotoxicity Syndromes | Diffuse Large B-Cell Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | YesCAR-Ta|Axicabtagene Ciloleucel|axi-cel |
| Co-treatment | defibrotide |
| Generation | 2nd |
| Phase | Phase2 |
| Recruitment status | Terminated |
| Title | A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity |
| Year | 2019 |
| Country | United States |
| Company sponsor | Jazz Pharmaceuticals |
| Other ID(s) | JZP395-201 |
| Vector information | |||||
|
|||||
| Cohort 1 | |||||||||||
|
|||||||||||